Prostate-specific antigen ( PSA ) response was the primary endpoint ; response assessment on the two arms was noncomparative and tested separately ; H0 = 0.45 versus HA = 0.60 ( = 0.05 ; = 0.09 ) for Arm A ; H0 = 0.05 versus HA = 0.20 ( = 0.05 , = 0.10 ) for Arm B2 .